Amplitude Surgical Admitted to the SRD “Long-seulement”

Long-only Defered Settlement Service

VALENCE, France--()--Regulatory News:

Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker: AMPLI, PEA-PME eligible), a leading French player on the global surgical technology market for lower-limb orthopedics, announces that its shares will be admitted to the Euronext Paris SRD (Service de Règlement Différé, i.e. Deferred Settlement Service) from 29 December 2015, on the “Long-seulement” (Long-only) segment.

With a minimum daily trading volume of €100,000 over the past year, a condition for being admitted to the SRD “Long-seulement” (Long-only Deferred Settlement Service), the liquidity of Amplitude Surgical shares has increased significantly as a result of regular communications of its performances.

In practical terms, the SRD “Long-seulement” will allow those with a French securities account to purchase Amplitude Surgical shares on margin using the leveraged effect of deferred settlement. For the buyer, risks are thus limited to the initial size of the investment.

Being admitted to the SRD “Long-seulement” will make Amplitude Surgical shares more attractive and will increase liquidity by providing access to a broader base of institutional and individual investors.

Next event: Shareholders’ Meeting, Wednesday December 9, 2015

Next financial press release: H1 2015/16 sales, Wednesday February 3, 2016

About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. Amplitude Surgical distributes its products in more than 30 countries. On June 30, 2015, Amplitude Surgical had a workforce of 248 staff and recorded sales of 71.1 million euros and an EBITDA margin of close to 19%.

Contacts

Amplitude Surgical
Philippe Garcia
Chief Financial Officer
philippe.garcia@amplitude-ortho.com
+33 (0)4 75 41 87 41
or
NewCap
Investor Relations
Marc Willaume
amplitude@newcap.eu
+33 (0)1 44 71 00 13
or
NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 98 55

Contacts

Amplitude Surgical
Philippe Garcia
Chief Financial Officer
philippe.garcia@amplitude-ortho.com
+33 (0)4 75 41 87 41
or
NewCap
Investor Relations
Marc Willaume
amplitude@newcap.eu
+33 (0)1 44 71 00 13
or
NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 98 55